KOLON LIFE SCIENCE Extends KDB Loan with Collateral from Affiliate Kolon Biotech, Aiming for Financial Stability

KOLON LIFE SCIENCE has extended a 19.5 billion KRW loan from Korea Development Bank using real estate and movable assets provided as collateral by its affiliate Kolon Biotech. This is a maturity extension of a loan originally executed in June 2023 and does not involve new funding.
The collateral limit is 12 billion KRW with a secured amount of 10 billion KRW, and the total outstanding balance including previous transactions is 18 billion KRW. The board resolved on June 24, 2026, with one outside director attending.
No shareholder return events are associated with this disclosure, and there is no issuance of new shares or change in capital structure. While the extension alleviates short-term liquidity risk, interest burden and debt dependency persist.
[AI Summary]This transaction is merely an extension of existing debt using affiliate collateral, resulting in no dilution of shareholder value. Although it supports financial stability, the lack of growth capital deployment limits positive impact, and no material improvement in long-term profitability is expected.